Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2907934 | 0.83 | HTR2C (0.42) | HTR2CHTR2BHTR2ACYP3A4POLB | |
| SCHEMBL2912736 | 0.82 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4POLB | |
| Hydrochloric Acid SCHEMBL2905245 | 0.81 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4POLB | |
| SCHEMBL16210108 | 0.81 | CYP3A4 (0.41) | HTR2CCYP3A4POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2908620 | 0.80 | CYP3A4 (0.37) | HTR2CHTR2BHTR2ACYP3A4CDK4 | |
| SCHEMBL13090227 | 0.80 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4OGA | |
| SCHEMBL13090224 | 0.80 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4OGA | |
| Hydrochloric Acid SCHEMBL2907881 | 0.79 | CYP3A4 (0.40) | HTR2CCYP3A4POLBSMN1; SMN2 | |
| Bromide SCHEMBL2910613 | 0.78 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4OGA | |
| Bromide SCHEMBL2912242 | 0.78 | HTR2C (0.36) | HTR2CHTR2BHTR2ACYP3A4OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | HTR2C 1/4885HTR2B 7/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.